Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
P/E ratio for Exact Sciences Corporation (EXAS)
P/E ratio as of 2023: -65.28
According to Exact Sciences Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -65.28. At the end of 2022 the company had a P/E ratio of -14.00.
P/E ratio history for Exact Sciences Corporation from 1998 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -65.28 |
| 2022 | -14.00 |
| 2021 | -22.39 |
| 2020 | -23.60 |
| 2019 | -144.52 |
| 2018 | -44.03 |
| 2017 | -53.13 |
| 2016 | -8.18 |
| 2015 | -5.39 |
| 2014 | -22.01 |
| 2013 | -17.05 |
| 2012 | -12.02 |
| 2011 | -14.87 |
| 2010 | -20.93 |
| 2009 | -12.23 |
| 2008 | -1.59 |
| 2007 | -7.26 |
| 2006 | -5.81 |
| 2005 | -4.00 |
| 2004 | -5.24 |
| 2003 | -6.75 |
| 2002 | -6.68 |
| 2001 | -7.20 |
| 2000 | -1.85 |
| 1999 | -2.82 |
| 1998 | -2.47 |